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Suppression of Myc-Induced Apoptosis in  Cells
Exposes Multiple Oncogenic Properties of Myc
and Triggers Carcinogenic Progression
cells is c-Myc, an essential part of normal cell prolifera-
tive machinery (Eisenman, 2001), expressed at low levels
throughout the cell cycle of proliferating, mitogen-stimu-
lated somatic cells. In most tumor cells, Myc expression
is deregulated, often markedly elevated, and no longer
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dependent upon mitogenic signaling, although in mostCoventry CV4 7AL
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is unknown. It is also unclear whether it is deregulation2 Imperial Cancer Research Fund Laboratories
or elevated expression that is critical in oncogenic acti-Lincoln’s Inn Fields
vation of c-Myc.London WC2A 3PX
Paradoxically, c-Myc is also a potent inducer of apo-United Kingdom
ptosis (Evan and Littlewood, 1998), especially in cells3 UCSF Cancer Center and Cancer
depleted of survival factors or subjected to stress—bothResearch Institute
likely prospects during tumorigenesis. However, the ex-2340 Sutter Street
tent to which such apoptosis actually restrains the onco-San Francisco, California 94143
genic potential of c-Myc remains unclear. Suppression
of apoptosis, for example by increased expression of
Bcl-2 (Bissonnette et al., 1992; Fanidi et al., 1992;Summary
Wagner et al., 1993), excess survival factors (Askew et
al., 1991; Evan et al., 1992; Harrington et al., 1994), orTo explore the role of c-Myc in carcinogenesis, we
genetic inactivation of ARF (Zindy et al., 1998) or p53have developed a reversible transgenic model of pan-
(Wagner et al., 1993, 1994) tumor suppressors, exacer-creatic  cell oncogenesis using a switchable form of
bates c-Myc-induced tumorigenesis (Blyth et al., 1995;the c-Myc protein. Activation of c-Myc in adult, mature
Eischen et al., 1999, 2001; Jacobs et al., 1999; Lotem cells induces uniform  cell proliferation but is ac-
and Sachs, 1995; Maestro et al., 1999; Pelengaris et al.,companied by overwhelming apoptosis that rapidly
1999; Schmitt et al., 1999; Strasser et al., 1990). How-erodes  cell mass. Thus, the oncogenic potential of
ever, it is unclear whether they do this by directly antago-c-Myc in  cells is masked by apoptosis. Upon sup-
nizing c-Myc-induced apoptosis or by nonspecificallypression of c-Myc-induced  cell apoptosis by coex-
protecting cells from the apoptotic consequences ofpression of Bcl-xL, c-Myc triggers rapid and uniform
genotoxic and other stresses (Eischen et al., 1999; Evanprogression into angiogenic, invasive tumors. Sub-
and Vousden, 2001; Sherr, 2000). The difficulties of di-sequent c-Myc deactivation induces rapid regression
rectly observing c-Myc-induced apoptosis in vivoassociated with vascular degeneration and  cell apo-
means that it has never been possible to evaluate theptosis. Our data indicate that highly complex neoplas-
contribution made in any tissue by Myc-induced apopto-tic lesions can be both induced and maintained in vivo
sis in early, middle, and late progression of Myc-inducedby a simple combination of two interlocking molecular
malignancies.lesions.
Pancreatic  cells comprise the major part of the sev-
eral hundred Islets of Langerhans, colonies of endocrineIntroduction
cells scattered throughout the exocrine pancreas, and
are the sole source of insulin.  cells sustain slow turn-
A wealth of data indicate that cancers are multistage
over throughout life with an estimated mean  cell life-
diseases progressing via protracted accumulation of
span (in the rat) of around 58 days (Bonner-Weir, 2001).
multiple lesions that compromise control of cell prolifer- Excess apoptosis is implicated in the  cell attrition that
ation, survival, differentiation, migration, and social in- accompanies some forms of diabetes, whereas excess
teractions with neighboring cells and stroma. Hanahan
 cell propagation is the hallmark of insulinoma (Pavelic
and Weinberg (2000) construed the axiomatic require- et al., 1996).
ments of cancer cells as the capacity to proliferate irre- The best-characterized paradigm of  cell carcino-
spective of exogenous mitogens, refractoriness to genesis is the elegant RIP-Tag transgenic model of Ha-
growth inhibitory signals, resistance to apoptosis, un- nahan and colleagues. In this model, targeted expres-
restricted proliferative potential (immortality), capacity sion of SV40 T antigens by the rat insulin promoter
to recruit a vasculature, and the ability to invade sur- induces consistent, kinetically reproducible yet spo-
rounding tissues and eventually metastasize. By impli- radic emergence of  cell neoplasms that progress with
cation, tumor progression proceeds by acquisition of diminishing frequency through defined stages of in-
lesions that provide the tumor cell with these attributes creasing “severity,” occasionally evolving into full-
and which thereby shape the complex phenotype of the blown, invasive  cell carcinomas. (Christofori and Ha-
tumor cell. nahan, 1994). RIP-Tag exploits a number of inherent
One frequent target for growth deregulation in cancer advantages offered by  cells as targets for transgenic
tumorigenesis.  cells have an intrinsically low prolifera-
tive rate, are exclusively targeted by the insulin pro-4 Correspondence: gevan@cc.ucsf.edu
5 These authors contributed equally to this work. moter, have a well-described and demarked ontogeny,
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and are dispersed throughout the pancreas amongst ous times. Virtually all  cells in every islet were prolifer-
ating within 24 hr of c-MycERTAM activation, as indicatedhundreds of spatially isolated islet colonies. This latter
uniquely permits discrimination between direct effects by positive nuclear staining for the proliferation marker
Ki-67. Proliferation was accompanied by significant, al-of the transgene, expected to arise synchronously in all
islets, and those due to stochastic secondary events, though incomplete, downregulation of insulin expres-
sion (Figure 2A). Continuous c-MycERTAM activation in-expected to emerge sporadically in isolated islets. Thus,
the sporadic and focal tumorigenesis exhibited in the duced sustained islet cell proliferation (see below). Thus,
activation of c-Myc is sufficient to elicit and maintainRIP-Tag model indicates that progression arises from
stochastic secondary lesions, some of which have been multiple rounds of  cell replication in vivo.
To assess the balance between c-Myc-induced prolif-defined (Hodgson et al., 2001).
We have developed a switchable model of Myc carci- eration and apoptosis in  cells in vivo, c-MycERTAM was
continuously activated in pIns-c-MycERTAM mice by dailynogenesis in  cells in which c-Myc function can be
rapidly switched on and off. This has allowed us to IP 4-OHT. Analysis of pancreata from representative
mice showed that sustained c-Myc activation triggeredexplore the direct consequences of c-Myc activation
and deactivation in mature  cells in vivo and assess the rapid islet involution. To determine the mechanism of
involution, pancreata were examined for the presencerelative importance of Myc-induced proliferation versus
apoptosis in inducing and maintainingcell tumorigene- of apoptotic cells both histologically, to identify con-
densed pyknotic nuclei, and by TUNEL staining, to iden-sis. We show that Myc-induced apoptosis is indeed a
powerful and effective innate restraint to Myc-induced tify fragmented DNA indicative of apoptotic cells. No 
cell apoptosis was evident in islets of untreated trans-tumorigenesis, whose suppression exposes multiple
neoplastic attributes of Myc and allows it to drive tumor genic mice (Figure 2B) or 4-OHT-treated wild-type ani-
mals (data not shown). In contrast, between 4% andprogression without the need for additional neoplastic
lesions. 7% of total islet cells appeared apoptotic by 72 hr of
c-MycERTAM activation (Figure 2B). Importantly, apopto-
sis arose to similar extents in each islet (see below) andResults
was restricted to  cells, leaving unaffected glucagon-
positive  cells concentrated in the islet periphery (Fig-Expression of Switchable c-Myc in Pancreatic 
ure 2B). Almost complete  cell ablation had occurredCells of Adult Transgenic Mice
after 6–10 days of sustained c-MycERTAM activation (Fig-We expressed a cDNA encoding human c-Myc fused
ure 2C). Such dramatic attrition occurred despite theat its C terminus to the hormone binding domain of
sustained induction of  cell proliferation by activated4-hydroxytamoxifen (4-OHT)-responsive mutant murine
c-MycERTAM (Figure 3A; note the few residual  cellsestrogen receptor (c-MycERTAM) (Littlewood et al., 1995)
remain Ki-67 positive and therefore remain in cell cycle),in pancreatic  cells under the control of an insulin pro-
unequivocally demonstrating that the proapoptotic ac-moter (pIns) (Figure 1A; Ohashi et al., 1991). Restricted
tivity of c-Myc predominates over its mitogenic capa-expression of c-MycERTAM protein to the nuclei of  cells
bility in this tissue. Importantly, islet involution waswas confirmed immunocytochemically using a rabbit
observed to occur with similar kinetics in all islets through-polyclonal anti-Myc antibody (pan-Myc) and was
out the pancreas (Figure 3B).blocked by preincubation of antibody with its original
Since pancreatic  cells are the sole source of hor-Myc peptide immunogen (see Figure 1B). Identical tissue
monal insulin required for blood glucose homeostasis,and subcellular localization was observed with poly-
c-Myc-induced suppression of insulin expression andclonal antibody specific for the ERTAM domain (not
destruction of  cells was mirrored by the acute onsetshown). We compared the level of c-MycERTAM protein
and maintenance of hyperglycemia (Table 1). Hypergly-expression in transgenic  cells with that in serum-stim-
cemia arose with similar kinetics in all mice, male andulated Swiss 3T3 (S3T3) cells (Moore et al., 1987) by
female. By contrast, both 4-OHT-treated wild-type micequantitative immunoblotting with pan-Myc antibody,
and untreated transgenic control mice maintained nor-which sees a conserved epitope present in c-MycERTAM
mal blood glucose levels throughout the experimentaland all Myc proteins of rodents and humans (Figure 1C).
period.Based on this, we estimate that each transgenic 
cell expresses between 4000 and 6000 molecules of
c-MycERTAM, comparable with the level of expression in Deactivation of c-MycERTAM Leads to Synchronous
primary serum-stimulated human fibroblasts such as Islet Regeneration and Recovery from Diabetes
MRC-5 (Moore et al., 1987). in pIns-c-MycERTAM Mice
c-MycERTAM activity is rapidly lost upon withdrawal of
4-OHT both in vitro (Littlewood et al., 1995) and in vivoc-Myc Activation Induces Proliferation in Adult
Pancreatic  Cells In Vivo, but This Is Rapidly (Pelengaris et al., 1999), allowing us to assess the effects
of c-MycERTAM deactivation on cell destruction. c-Myc-Overwhelmed by Apoptosis
 cells of non-4-OHT-treated transgenic mice exhibited ERTAM was activated for 6 days, resulting as before in
rapid  cell attrition (Figure 3A) accompanied by acuteintense insulin immunostaining and no evident cell pro-
liferation (Figure 2A), identical to  cells from adult wild- hyperglycemia (Table 1). 4-OHT was then withdrawn
and blood and urinary glucose were monitored daily,type mice (not shown). To explore the mitogenic action
of c-Myc in adult  cells in vivo, 4-OHT was administered together with histological analysis of pancreata from
representative mice. Within 6–9 days of 4-OHT with-by daily intraperitoneal (IP) injection to pIns-c-MycERTAM
mice and pancreata from the animals analyzed at vari- drawal, we observed marked regeneration of pancreatic
c-Myc Induces Carcinogenic Progression in  Cells
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Figure 1. Generation and Characterization of Insulin-c-MycERTAM Transgenic Mice
(A) Construction of pIns-c-MycERTAM transgene. cDNA encoding human c-myc fused to the modified estrogen receptor ligand binding domain
(ERTAM) (Littlewood et al., 1995) was cloned, along with -globin polyA site, downstream of the rat insulin promoter (pIns) (Ohashi et al., 1991).
Comparative Southern blotting indicates that the founder line used in all studies carries 10 copies of the pIns-c-MycERTAM transgene.
(B) c-MycERTAM protein expression is restricted to pancreatic islet  cells. Immunocytochemical staining of sequential frozen pancreatic
sections from transgenic mice were stained with Pan-Myc antibody (left), Pan-Myc antibody incubated with 10 g/ml Pan-Myc peptide
immunogen (middle), or insulin antibody (right).
(C) Comparison of c-MycERTAM protein levels in pancreatic islets with endogenous c-Myc in serum-stimulated Swiss 3T3 fibroblasts. Lysates
were prepared from hand-picked islets isolated from non-4-OHT-treated pIns-c-MycERTAM  RIP-BclxL (inactive c-MycERTAM) transgenic mice.
Swiss 3T3 were serum deprived for 48 hr (lane 1) and then stimulated with 10% fetal calf serum for 2 hr (lane 2), after which whole-cell lysates
were prepared. From each lysate, 105 cell equivalents were fractionated on a 10% polyacrylamide gel, electroblotted onto PVDF membrane,
and probed with Pan-Myc antibody. In transgenic islets, Pan-Myc antibody identifies the 95 kDa band corresponding to c-MycERTAM protein
(lane 3). As expected for a quiescent tissue, no appreciable endogenous 62 kDa c-Myc is expressed. In serum-stimulated S3T3 cells, Pan-
Myc antibody identifies the expected 62 kDa c-Myc protein.
islets (Figure 3A) accompanied by normalization of the mitochondrial apoptotic pathway, which is the ulti-
blood glucose (Table 1). Regeneration was accompa- mate conduit of both the ARF/p53-dependent (Zindy et
nied by the appearance of proliferating (Figure 3A, al., 1998) and -independent (Juin et al., 1999) c-Myc
arrows) cells, mainly in pancreatic ducts adjacent to proapoptotic effector pathways.
involuted islets. In the absence of 4-OHT, pIns-c-MycERTAM/RIP-Bcl-xL
double transgenic mice exhibited normal islet morphol-
ogy (Figures 3B and 4A) with no measurable  cell prolif-Rapid and Uniform c-Myc-Induced Tumor
eration or apoptosis (data not shown) and normal bloodProgression upon Suppression of 
glucose (Table 1). As in pIns-c-MycERTAM single trans-Cell Apoptosis
genic mice, activation of c-MycERTAM in pIns-c-MycERTAM/Our data imply that apoptosis acts as a formidable bar-
RIP-Bcl-xL double transgenic mice induced rapid andrier to the oncogenic potential of c-Myc in pancreatic 
synchronous entry into the cell cycle of virtually allcellscells. Therefore, to explore the consequences of activa-
in all islets (not shown). However, in dramatic contrast totion of c-Myc when apoptosis is suppressed, we
pIns-c-MycERTAM mice, we observed no c-Myc-inducedcrossed our pIns-c-MycERTAM mice with mice expressing
apoptosis but instead an immediate and progressivethe Bcl-2 homolog Bcl-xL, under direction of the rat insu-
lin promoter (RIP7) (Zhou et al., 2000). Bcl-xL suppresses expansion of  cells in all islets; within 7 days, histologi-
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Figure 2. Activation of c-MycERTAM Induces  Cell Proliferation and Apoptosis in Pancreatic  Cells In Vivo
(A) c-MycERTAM activation induces  cell proliferation and insulin downregulation. Paraffin-embedded fixed sections of pancreata, from either
untreated pIns-c-MycERTAM transgenic or pIns-c-MycERTAM mice treated with 4-OHT for 24 hr, were probed with antibodies specific for the
proliferation marker Ki-67 or for insulin.
c-Myc Induces Carcinogenic Progression in  Cells
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Figure 3. Effects of Myc Activation Arise Synchronously in All Islets and Are Reversible
(A) Ki-67 staining of involuted and regenerated islets. Left: representative involuted islet obtained from pIns-c-MycERTAM transgenic mouse
pancreas after 6 days continuous activation of c-MycERTAM. Note the few remaining  cells are Ki-67 positive (arrows). Right: after 6 days
continuous c-MycERTAM activation, administration of 4-OHT was withdrawn, mice were allowed to recover for 9 days and then sacrificed, and
pancreata were fixed, sectioned, and stained. A representative regenerated islet is shown. Note the presence of occasional proliferating (ki67-
positive)  cells (arrows) in ducts and regenerating islets. Scale bar equals 50 m.
(B) Low-power microscopic analysis of effects of Myc activation. pIns-c-MycERTAM and pIns-c-MycERTAM/Bcl-xL transgenic mice were either
untreated or treated for 7 days with 4-OHT to activate c-MycERTAM. Pancreata were isolated, fixed, sectioned, stained for insulin immunoreactiv-
ity, and examined under low power. Scale bar equals 200 m.
cal examination of 4-OHT-treated pIns-c-MycERTAM/RIP- cumulation of multiple somatic lesions that confer di-
verse and novel properties on tumor cells such as lossBcl-xL double transgenic pancreata showed grossly hy-
perplastic islets distributed throughout the pancreas of differentiated phenotype, angiogenesis, and inva-
siveness. We therefore asked whether, and with what(Figure 3B). Thus, blocking c-Myc-induced apoptosis in
 cells by Bcl-xL expression transforms c-Myc from a frequency, c-Myc drove tumor progression in pIns-c-
MycERTAM/RIP-Bcl-xL cells. Since Myc inhibits differen-net growth suppressor to a growth inducer.
Tumor progression is generally thought to involve ac- tiation in multiple cell lineages, we first examined the
(B) c-MycERTAM-induced islet involution involves  cell apoptosis. Sections from pancreata from either untreated pIns-c-MycERTAM mice or
from pIns-c-MycERTAM mice treated with 4-OHT for 72 hr were analyzed for apoptotic DNA by TUNEL or probed with antibodies specific for
insulin or glucagon.
(C) Sustained c-MycERTAM activation induces islet involution. Comparison of representative H&E-stained paraffin-embedded sections from
pIns-c-MycERTAM transgenic pancreata either untreated or treated with 4-OHT for 6 days. Scale bar equals 50 m.
Cell
326
Table 1. Onset and Recovery of Diabetes (Hyperglycemia) in pIns-c-mycERTAM and pIns-c-MycERTAM/Bcl-xL Mice
Duration of 4-OHT Treatment
9 Days after
0 Days 6–9 Days 23 Days 42 Days 50 Days 4-OHT Withdrawal
Mouse Genotype Mean Blood Glucose (mMol/L) (SEM)
Wild-type 11.7 (1.02) 9.3 (0.94) 9.32 (0.41) ND ND 9.3 (0.3)
MycERTAM 9.82 (1.05) 30.58 (1.48) 32 (1.3) ND ND 8.67 (0.47)
Bcl-xL 11.9 (0.35) 12.3 (0.27) 11.53 (0.55) 8.81 (0.51) 8.87 (1.1) ND
MycERTAM/Bcl-xL 6.2 (0.91) 24.1 (3.3) 14.42 (1.95) 5.54 (1.35) 2.84 (0.18) ND
Fasting blood glucose measurements (mMol/l) were taken at specific time points from wild-type mice or transgenic mice following c-MycERTAM
activation or subsequent deactivation. All experimental groups consisted of both male and female littermates between 3 and 8 months of
age. Activation of c-MycERTAM protein for 6–9 days led to onset of diabetes in pIns-c-MycERTM mice, as indicated by elevated blood glucose.
Subsequent deactivation of c-MycERTAM led to rapid normalization of blood glucose within 9 days. pIns-c-MycERTM/Bcl-xL double transgenic
mice exhibited only transient hyperglycemia, becoming hypoglycemic by 40–50 days of c-Myc activation.
effect of c-Myc activation on  cell differentiation status. lin to reestablish normoglycemia. Thus, activation of
c-Myc is sufficient to at least partially revert the differen-Expression of insulin, a hallmark of mature differentiated
 cells, was rapidly although incompletely downregu- tiated phenotype of mature  cells.
It is proposed that inability to generate requisite vas-lated in  cells following c-MycERTAM activation (Figures
2A and 4A). Such downregulation is presumably respon- culature is a major restraint to the unbridled expansion
of neoplastic cells (Folkman, 1992). We therefore nextsible for the transient increase in fasting blood glucose
levels seen in double transgenic mice (Table 1), while assessed the angiogenic status in hyperplastic islets
from pIns-c-MycERTAM/RIP-Bcl-xL double transgenictheir subsequent recovery is due to the progressively
increasing numbers of  cells which, despite their low mice treated for 7 days with 4-OHT. Histological analysis
indicated the presence of an extensive network of bloodindividual expression, together produce sufficient insu-
Figure 4. Characterization of c-MycERTAM/
Bcl-xL  Cell Tumors
(A) c-Myc activation triggers rapid  cell hy-
perplasia, loss of differentiated phenotype,
angiogenesis, and downregulation of E cadh-
erin with loss of cell-cell contact. pIns-c-
MycERTAM  RIP-Bcl-xL double transgenic
mice were treated with 4-OHT daily for 7 days
to drive sustained c-MycERTAM activation.
Pancreata were removed, fixed, and stained
by H&E and/or insulin or E cadherin antibod-
ies, as appropriate. Dotted white line marks
extent of  cell mass. Scale bar equals 50
m.
(B) Immunoblot analysis of E cadherin ex-
pression following c-Myc activation. Islets
were isolated from control and 0- and 8-day
4-OHT-treated c-MycERTAM/Bcl-xL double
transgenic mice, equivalent cell numbers
were lysed and fractionated by SDS-PAGE,
and E cadherin levels were assessed by im-
munoblotting.
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Figure 5. c-MycERTAM/Bcl-xL  Cell Tumors Are Invasive
c-MycERTAM was continuously activated in c-MycERTAM/Bcl-xL double transgenic mice for 2–8 weeks, and pancreata from representative mice
were fixed, sectioned, and analyzed histologically and immunohistochemically as shown. By 2 weeks of c-Myc activation, locally invasive,
insulin-positive  cells were evident in at least 50% of islets per section (A). By 6 weeks, much of the exocrine pancreas had become eroded
and replaced by  cell tumors (B and C). Staining at 8 weeks revealed multiple ectopic deposits of Nkx6.1- or Isl-1-staining cells in blood
vessels, pancreatic ducts, and draining mesenteric lymph nodes (D–F).
vessels permeating the entirety of every islet (Figure and rate-limiting role in the transition from benign  cell
adenoma to malignant carcinoma in the RIP-Tag model4A), which was confirmed by staining with the vascular
endothelial marker CD31 (not shown). Only modest vas- (Perl et al., 1998). Islets from either wild-type (not shown)
or untreated pIns-c-MycERTAM/RIP-Bcl-xL double trans-cularization was evident in islets from control mice in
which c-MycERTAM was inactive. Angiogenesis arose genic mice (inactive Myc) exhibit intense E cadherin cell
surface staining (Figure 4A). By contrast, within 7 dayswith similar kinetics in each islet, its extent keeping pace
with  cell expansion even during prolonged activation of c-Myc activation, we observed a dramatic reduction in
E cadherin immunostaining in islets of pIns-c-MycERTAM/of c-MycERTAM (Figure 5B). We conclude that activation
of c-Myc elicits an angiogenic response coincident with RIP-Bcl-xL double transgenic mice. Immunoblotting of
isolated islets confirmed that c-Myc induced progres-its induction of  cell hyperplasia.
Perhaps the most lethal attribute of malignant tumor sive loss of E cadherin protein from  cells (Figure 4B).
Loss of E cadherin coincided with dramatic withdrawalcells is their ability to detach, invade surrounding tissue,
and eventually metastasize. The principal intercellular of  cell-cell contacts throughout all islets of double
transgenic mice (most obvious in Figures 4A and 5B).adhesion molecule in epithelia is E cadherin, whose ex-
pression is lost in invasive human epithelial cancers The rapid and synchronous induction of dedifferentia-
tion, angiogenesis, and loss of cell-cell contact in each(Birchmeier et al., 1995; Christofori and Semb, 1999;
Takeichi, 1993). Indeed, loss of E cadherin plays a causal of the spatially separated islets in the pancreas implies
Cell
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Figure 6. Regression of  Cell Tumors after c-Myc Deactivation
(A) c-Myc deactivation induces  cell growth arrest, vascular collapse, apoptosis of vessels walls and  cells, and eventual tumor involution.
pIns-c-MycERTAM/RIP-Bcl-xL double transgenic mice were treated IP with 4-OHT daily for 14 days. Administration of 4-OHT was then stopped,
and representative mice were sacrificed immediately or after 4, 10, or 38 days. Pancreata were removed, fixed, and examined histologically
by H&E staining and immunohistochemically using anti-Ki-67 or anti-laminin antibodies and by Nkx6.1 or laminin (red) together with TUNEL
(green).
(B) E cadherin expression is restored rapidly following c-Myc deactivation. pIns-c-MycERTAM  RIP-Bcl-xL double transgenic mice were treated
IP with 4-OHT daily for 14 days. Administration of 4-OHT was then stopped, and representative mice were sacrificed after 3, 5, 10, and 38
days. Sections of their pancreata, together with sections from a double transgenic mouse never treated with 4-OHT (Never Myc), were probed
with anti-E cadherin.
that these attributes of more advanced malignancy are human insulinoma due to inappropriately excessive insulin
secretion, due probably to massively expanded numbersdirect consequences of c-Myc activation rather than the
outcome of sporadic secondary mutations. To explore of  cells. Because of c-Myc-induced suppression of in-
sulin expression, we used antibodies specific for the further this pleiotropic tumorigenic potential of c-Myc,
pIns-c-MycERTAM/RIP-Bcl-xL double transgenic mice cell lineage markers Nkx6.1 and Isl-1 to identify and
locate metastatic  cells. Ectopic  cells were evidentwere subjected to sustained c-Myc activation for ex-
tended periods up to 12 weeks. Within 2 weeks, local in multiple local blood vessels (Figure 5D), pancreatic
ducts (Figure 5E), and draining mesenteric lymph nodesinvasion by insulin-positive cells was evident in at least
50% of islets (e.g., Figure 5A). By 6 weeks of sustained c- (Figure 5F).
Myc activation, pancreata had become filled with multi-
ple, large, intensely vascularized tumors (Figure 5B) with Rapid Regression of  Cell Tumors Following
c-Myc Deactivationmultiple areas of localized  cell invasion (Figure 5C).
As before,  cells in these tumors expressed reduced To determine whether c-MycERTAM activation was re-
quired to maintain  cell neoplasia, c-Myc was continu-insulin and undetectable E cadherin. Concomitant with
widespread development of  cell tumors, all mice devel- ously activated in 30 pIns-c-MycERTAM/RIP-Bcl-xL mice
for 14 days to induce  cell tumors. Twelve mice wereoped fasting hypoglycemia (Table 1), a common feature of
c-Myc Induces Carcinogenic Progression in  Cells
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sacrificed and all exhibited hypeplastic, angiogenic tu- E cadherin, and reattachment of  cells together with
mors with local invasion evident in at least 50% of islets involution of supernumerary and ectopic  cells, proba-
in each section. c-Myc was then deactivated by 4-OHT bly triggered by vascular collapse. These data clearly
withdrawal, representative mice (n  4) were sacrificed demonstrate that c-Myc is required not only to induce
at 4 and 10 days, and  cell masses were examined but also to maintain multiple aspects of neoplastic pro-
histologically together with the status of  cell prolifera- gression.
tion, apoptosis, insulin and E-cadherin expression, and
angiogenesis. Remaining mice were left for 1 month Discussion
before sacrifice and analysis. Multiple sections were
examined from each mouse, and representative images Expression of Conditional c-Myc Protein
are shown in Figure 6. in Pancreatic  Cells
By day 4 of 4-OHT withdrawal, most  cells had left To investigate directly the potential role of c-Myc-induced
cell cycle, as judged by Ki-67 staining, and insulin ex- apoptosis in tumor suppression, as well as to mimic
pression had returned to control levels in the smaller  more accurately the acute somatic activation of onco-
cell hyperplasias, although it remained weaker in the genes in intact tissues that causes adult cancers, we
larger  cell masses (not shown). We also observed targeted expression of a switchable, 4-OHT-dependent
reestablishment of  cell-cell contact, which correlated c-MycERTAM protein to pancreatic  cells. Immunohisto-
with the reexpression of E cadherin. Costaining of vascular chemical analysis confirmed uniform expression of
basal lamina with anti-laminin antibodies together with c-MycERTAM restricted to pancreatic  cells and at a low
TUNEL revealed numerous apoptotic cells in vessel walls, level similar to that in serum-stimulated primary human
particularly in larger  cell masses, while costaining of MRC-5 fibroblasts (Moore et al., 1987). Consequently,
Nkx 6.1  cell-specific antibody with TUNEL identified all the proneoplastic and proapoptotic effects we ob-
apoptotic  cells (1%–2%). Many of the hyperplastic serve in this in vivo  cell model arise from c-Myc dereg-
islets exhibited cavities filled with extravasated erythro- ulation rather than overexpression.
cytes, presumably caused by collapse of blood vessels
and death of  cells. In addition, small numbers of Ki-67- Activation of c-Myc Alone Is Sufficient to Induce
positive polymorphonuclear leucocytes and macro-  Cell Proliferation In Vivo
phages could be identified within islet blood vessels. In the absence of 4-OHT, expression of c-MycERTAM ex-
By 10 days of c-MycERTAM deactivation, all  cells were erts no observable effect on islets, as determined by
strongly positive for insulin (not shown) and E cadherin gross islet morphology or size, distribution of , , and
while remaining Ki-67 negative. Staining with laminin  cells within each islet, distribution and number of islets
antibody indicated dramatic loss of vessel integrity and within the whole pancreas, and extent of  cell prolifera-
marked disruption of normal vascular architecture, ac- tion or apoptosis. In contrast, activation of c-MycERTAM
companied by significant numbers of inflammatory cells triggered rapid and synchronous onset of proliferation
within and adjacent to the blood vessels.  cell apopto- in essentially all  cells in all islets. Furthermore, sus-
sis was also evident with sizeable erythrocyte-filled cavi- tained c-MycERTAM activation provoked sustained prolif-
ties present in almost all tumors. Over the ensuing 2 eration of  cells through multiple replicative rounds.
weeks, vasculature continued to degenerate and tumors Importantly, proliferation was not limited to any subpop-
shrank further, eventually leading to complete apparent
ulation of potential islet stem cells. We conclude that
reversal of  cell hyperplasia by 38 days (Figure 6).
Myc activation is capable of commandeering requisite
To explore the consequences of Myc deactivation on
accessory proliferative machinery needed for adult ectopic  cells that had invaded ducts, vessels, and
cell proliferation in vivo in the absence of overt activationlymph nodes, at least 20 mice were treated for 8 weeks
of other mitogenic pathways.(or longer) with continuous 4-OHT. All mice exhibited
profound hypoglycemia, indicative of excessive insulin
c-Myc Alone Is a Net Growth Suppressor in  Cellsproduction arising from heavy  cell tumor burden. As
The physiological relevance of Myc-induced apoptosisin Figure 5, exhaustive analysis involving at least 50
as a tumor suppressive mechanism in vivo has beensections from various planes throughout the length of
unclear. This uncertainty is further compounded by theeach pancreas from five mice revealed multiple ectopic
fact that c-Myc-induced apoptosis is regulated by sur-Nkx6.1-positive cell clusters in local lymph nodes, ves-
vival factors that vary both in availability and kind insels, and ducts in all animals. c-Myc was then deacti-
different tissues. For example, activation of c-Myc invated and blood glucose followed weekly to assess tu-
suprabasal keratinocytes in vivo triggers proliferationmor burden. By 4 weeks, all animals recovered and
without apoptosis because of an excess of local survivalretained normoglycemia. After a further 3 months, two
factors (Pelengaris et al., 1999). In complete contrast,animals were sacrificed and subjected to exhaustive
activation of only low levels of deregulated c-Myc in histological analysis of at least 50 sections, each with
cells triggered rapid onset of apoptosis, which over-multiple islets. In both animals, islet morphology, size,
whelmed proliferation and quickly led to attrition of and E cadherin staining were normal, and examination
cells and the onset of diabetes. The overall extent andof multiple sections failed to reveal any ectopic  cells
rate of c-Myc-induced  cell apoptosis was similar inin vessels, ducts, or mesenteric nodes. Some 80 other
each islet. Such dramatic differences in the effects ofanimals undergoing similar regression remained healthy
c-Myc in skin andcells in vivo illustrate the fundamentallyand normoglycemic thereafter.
different responses of cells in differing tissues to growthThus, regression following c-Myc deactivation in-
volved growth arrest, redifferentiation, reexpression of deregulating lesions, differences that must have a pro-
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found influence on the evolutionary pathways by which addition, however, c-Myc upregulates ID2 which, as a
generic quencher of multiple bHLH lineage-specifyingtumors evolve in each somatic setting. The facile induc-
tion of apoptosis by only low levels of c-Myc indicates transcription factors (Lasorella et al., 2000), has the po-
tential to interfere with multiple differentiation programs.that apoptosis can, indeed, act as a highly effective
tumor suppressive mechanism in  cells. This is most c-Myc has also been shown to be angiogenic in multi-
ple cells types, both through its repression of the angio-graphically demonstrated by the synchronous and ex-
peditious regeneration of  cells that follows c-Myc de- genesis inhibitor Thrombospondin-1 (Janz et al., 2000;
Ngo et al., 2000) and its induction of VEGF (Brandvoldactivation, presumably triggered by endocrine homeo-
static influences analogous to those that regulate  cell et al., 2000; Breit et al., 2000; Fotsis et al., 1999; Harris
et al., 2000; Pelengaris et al., 1999). Indeed, emergingmass during development and throughout adult life.
evidence suggests that many oncogenic lesions, includ-
ing c-Myc, are innately angiogenic through their abilitiesSuppression of Apoptosis Transforms c-Myc
to induce expression of the angiogenic transcriptioninto a Potent Oncoprotein that Drives Rapid
factor HIF1 (Semenza, 2002). A direct role for c-MycTumor Progression
in promoting angiogenesis is also strongly supportedTo test directly the importance of c-Myc-induced apo-
by our observation that c-Myc deactivation triggers theptosis in tumor suppression in  cells, we inhibited apo-
rapid collapse of  cell tumor vasculature, although theptosis by coexpression of Bcl-xL. The consequence was
precise mechanism awaits further analysis.dramatic—in place of involution, c-Myc activation in-
Finally, our own data show that a direct consequenceduced immediate and progressive  cell expansion in
of c-Myc activation is the downregulation of the intercel-all islets. At least two discrete effector pathways mediate
lular adhesion molecule E cadherin in  cells. Since Ec-Myc-induced apoptosis. One involves the transcrip-
cadherin downregulation is causally linked to sporadictional induction of the tumor suppressor ARF, which
emergence of invasive  cell carcinomas in the RIP-Tagincapacitates the p53 antagonist Mdm-2 and so triggers
model (Perl et al., 1998), as well as in most tumors ofaccumulation of p53 (Zindy et al., 1998). The other in-
epithelial origin (Christofori and Semb, 1999), its repres-volves a p53-independent proapoptotic action through
sion by c-Myc offers a direct potential mechanism byunknown effectors that primes mitochondria for release
which the oncoprotein promotes  cell invasion.of proapoptotic factors such as holocytochrome c (Juin
et al., 1999). Since Bcl-xL suppresses the mitochondrial
apoptotic pathway, its efficacy at blocking c-Myc- All In Vivo Effects of c-Myc Are Reversible
A great advantage of the short plasma half-life of 4-OHT isinduced apoptosis in  cells intimates that all down-
stream c-Myc apoptotic effector pathways, both p53- that cessation of 4-OHT administration leads to the rapid
deactivation of c-MycERTAM in vivo. In single c-MycERTAMdependent and -independent, are channeled through
the mitochondria. transgenics where c-Myc activation triggers overwhelm-
ing  cell apoptosis, subsequent c-MycERTAM deactiva-As the  cell tumors expand under the combined influ-
ence of c-Myc and Bcl-xL, they seamlessly, rapidly, and tion triggers synchronous  cell and islet regeneration.
The most likely source of these regenerating  cells isspontaneously acquire attributes of more advanced
neoplasia, including dedifferentiation, angiogenesis, tis- probably some  cell precursor whose insulin negativity
spares it from the lethal effects of c-Myc expressionsue disorganization, and invasion. Moreover, such tu-
mor progression arises rapidly and with similar kinetics and which, from the location of proliferating cells during
 cell regeneration, probably resides in the pancreaticin each of the hundreds of spatially separated islets
within the pancreas. Even local invasion, by necessity ducts. However, the precise lineage and nature of the
regenerative cell remains unknown.a focal process, is sufficiently widespread to be evident
in over half of the hyperplastic islets in each tissue plane In c-MycERTAM/Bcl-xL double transgenics, c-MycERTAM
activation elicits immediate and progressive  cell neo-examined. The uniformity and rapidity of such progres-
sion indicates that it is very unlikely to arise through plasia in all islets. However, even after 2–3 weeks of
continuous c-Myc activation, over which time multiplestochastic secondary lesions, which would be expected
to arise focally within individual islets after protracted angiogenic and locally invasive tumors form, deactiva-
tion of c-Myc leads to general regression of tumorsperiods, as they do in the RIP-Tag model (Christofori
and Hanahan, 1994). back to phenotypically normal, fully functional, insulin-
positive, quiescent islets with normal levels of E cadh-Our conclusion is that c-Myc must directly elicit in
each  cell those attributes, such as dedifferentiation, erin. We conclude from this that all the neoplastic para-
phernalia we observe in the hyperplastic c-Myc/Bcl-xLangiogenesis, and invasion, that drive the observed tu-
mor progression. In fact, such properties are consistent  cell tumors, including dedifferentiation, invasion, and
angiogenesis, remain completely dependent upon sus-with some of the known activities described for c-Myc.
For example, c-Myc antagonizes differentiation in multi- tained c-Myc activity for their support and maintenance.
Interestingly, regression is also accompanied by sub-ple cell lineages including  cells, where we show it
triggers rapid downregulation of insulin and PDX-1, both stantial infiltration of inflammatory cells that may be
responsible for phagocytosis and clearance of apoptoticde facto markers of  cell differentiation. A potential
mechanism for this is suggested by the recent report and/or necrotic debris.
Detailed kinetic analysis suggests that regression isthat c-Myc may directly interfere with the action of the
 cell-specifying bHLH transcription factor Beta2/ mediated, at least in great part, by rapid collapse of
vasculature that triggers death of excess  cells. SuchNeuroD by inhibiting its binding to a consensus E box
element in the insulin promoter (Kaneto et al., 2002). In rapid disassembly of vasculature is most consistent with
c-Myc Induces Carcinogenic Progression in  Cells
331
a direct angiogenic role for c-Myc, as proposed above. drive tumor cell proliferation but, in addition, orchestrate
many of the general attributes that expanding somaticHowever, it is also possible that  cell growth arrest
following Myc deactivation allows intrinsic antineoplas- cells will require to establish themselves within the
soma. It remains to be seen whether such pleiotropictic mechanisms such as the immune response to initiate
regression. Another possibility is that cell redifferentia- properties are peculiar to c-Myc or are shared by other
factors that promote cell expansion, including onco-tion renders supernumerary  cells prey to such homeo-
static forces as normally restrict  cell mass. In this genic lesions in the Ras and E2F pathways. However,
recent studies with other switchable oncogene trans-context, it is especially intriguing that regressing  cell
tumors return to normal islet size and morphology, illus- genic models reinforce the notion that incapacitating
the driving oncogenic lesion can lead to expeditioustrating that  cell mass is stringently and adaptively
regulated, at least within the pancreas. regression of tumors induced in many different tissues
by c-Myc (Felsher and Bishop, 1999; Pelengaris et al.,
1999), Ras (Chin et al., 1999; Fisher et al., 2001), orc-Myc and Tumor Progression
even T antigens (Berkovich and Efrat, 2001). At least inThe best-established and -characterized transgenic
principle, therefore, the complexity of the tumor pheno-model of  cell carcinogenesis is the elegant RIP-Tag
type need not be instructed by an equivalent complexitysystem developed by Hanahan and colleagues in which
of genetic or epigenetic alteration. Rather, cancers mayexpression of the SV40 early region encoding large and
be underpinned by only a modest number of interdepen-small T antigens is targeted to pancreatic  cells using
dent, pleiotropic lesions that present themselves as mis-the rat insulin promoter (Christofori and Hanahan, 1994).
sion-critical targets for effective cancer therapies.RIP-Tag mouse islets appear phenotypically normal at
birth, but hyperplastic islets emerge stochastically at
Experimental Proceduresaround 3–4 weeks of age. Such enlarged islets exhibit
hyperproliferation, presumably driven by expression of
pIns-c-MycERTAM Transgene ConstructionSV40 T antigens, together with features of dysplasia and
A full-length human c-myc cDNA fused to the hormone binding
carcinoma in situ. Only some 10% of hyperplastic islets domain of a modified estrogen receptor, c-MycERTAM, has been
eventually switch to an angiogenic phenotype and fewer described previously (Littlewood et al., 1995). The insulin promoter
still develop into solid adenomas, while progression to construct (Ohashi et al., 1991) was a kind gift from T. Moroy and
R.M. Zinkernagel and comprises 0.7 kb of the rat insulin promoterinvasive carcinoma is very rare. Thus, as with many other
and 1.6 kb of the -globin polyadenylation sequence (Figure 1A) intransgenic oncogene mouse models, tumor progression
a puc18 backbone. c-MycERTAM DNA was excised from pBluescriptin RIP-Tag mice is sporadic, protracted, and sequential,
as an EcoRI fragment and blunt-ended with T4 DNA polymerase.
consistent with the general view that tumors arise The insulin promoter cassette was cut with BamH1 and blunt-ended
through the stochastic accumulation of multiple muta- with T4 polymerase, and the c-MycERTAM sequence was inserted.
tions, each of which confers its own neoplastic signature Since no unique restriction sites were present in the parent plasmid
vector (puc18), the insert was excised from puc18 vector with SmaIon the developing neoplasm.
and HindIII to generate two fragments (SmaI-SmaI and SmaI-HindIII)Our acute c-Myc activation  cell model clearly differs
that were subsequently subcloned into the SmaI-HindIII site ofdramatically from the RIP-Tag model. Instead of spo-
pBluescript in a 3-way ligation. The final transgene unit was then
radic malignant progression, acute activation of c-Myc excised from pBluescript as a NotI-HindIII fragment (4.6 kb). Puri-
triggers immediate and ubiquitous neoplastic progres- fied DNA was resuspended for pronuclear injection in sterile injec-
sion in all islets so long as c-Myc-induced apoptosis is tion buffer (10 mM Tris, 0.1 mM EDTA [pH 7.4]) at a concentration
of 5 ng/l.suppressed. The speed and uniformity of such malig-
nant progression in so many spatially isolated  cell
masses within the pancreas precludes a role for second- Generation of pIns-c-MycERTAM Transgenic Mice
and Estimation of Transgene Copy Numberary lesions, at least for the development of dedifferenti-
pIns-c-MycERTAM DNA was injected into male pronuclei of dayated, angiogenic, and invasive tumors. Rather, such at-
1-fertilized (CBA  C57BL/6)F1 embryos. Injected embryos weretributes appear to be direct consequences of c-Myc
transferred into day 1-plugged pseudopregnant foster mice, and
activation in affected  cells which, by virtue of their the litters were screened for presence of the transgene by Southern
deregulated proliferation and suppressed apoptosis, blotting. Heterozygous founder mice were backcrossed appropri-
spontaneously acquire the capacity to generate the req- ately to establish transgenic lines.
For Southern blot analysis, genomic DNA isolated from mouseuisite blood supply and somatic space for their expan-
tails (3 mm) was digested overnight with BamHI and EcoRI to excisesion. Since the RIP-Tag and pIns-c-MycERTAM/Bcl-xL
a fragment of approximately 1.8 kb, fractionated on a 1% agarosetransgenic models differ both in the oncogenes driving
gel, transferred to a Hybond-N filter (Amersham), and probed with
tumorigenesis and in the manner and timing of their a 32P-radiolabeled 1.2 kb human c-myc cDNA. Transgene copy num-
activation, either or both of these differences may con- ber was estimated by densitometric comparison of the 1.8 kb ex-
tribute to the dramatic differences in rate, extent, and cised transgene fragment with the endogenous single-copy 2 kb
E immunoglobin heavy chain gene excised by EcoRI-digestion ofuniformity of tumor progression in each model. Nonethe-
genomic DNA.less, our data demonstrate unequivocally that complex
neoplastic phenomena involving both the affected tu-
Genotype Analysis of pIns-c-MycERTAM and RIP7-Bcl-xLmor cells and its interactions with normal tissues can
Transgenic Micebe both induced and maintained by a very limited plat-
Heterozygous RIP7-Bcl-xL transgenic mice were obtained from Dr.form of interlocking pleiotropic mutations that, mini-
Doug Hanahan (UCSF). Litters from both pIns-c-MycERTAM and RIP7-
mally, drive cell proliferation and incapacitate concomi- Bcl-xL transgenic mice and appropriate F1 crosses were routinely
tant apoptosis. It is also clear that growth deregulating genotyped by PCR analysis on genomic DNA isolated from mouse
tails.lesions such as activated c-Myc do far more than merely
Cell
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Histological and Immunohistochemical Analysis lysed in an equal volume (50–100 l) of SDS-PAGE sample buffer
(Laemmli, 1970) and denatured by brief boiling, and 5–10 g totalof Pancreatic Tissue
Pancreata were excised from mice, and 5 mm pieces of tissue were protein was fractionated on a 7.5% PAGE-SDS gel and transferred to
a PVDF membrane (NEN Life Science Products) by electroblotting.fixed overnight in neutral-buffered formalin, embedded in paraffin
wax, and sectioned (5–10 m). Frozen sections were prepared from Filters were incubated in 5% nonfat dried milk (Marvel, Cadbury) in
PBS  0.1% Tween-20 for 1 hr at room temperature and then intissue fixed in 4% paraformaldehyde for 4 hr, transferred to cold
30% sucrose in PBS overnight at 4C, embedded in OCT, and frozen appropriate antibody in PBS containing 1% nonfat dried milk and
0.1% Tween-20 overnight at 4C. Filters were washed in PBS in foil on a bath of dry ice and ethanol. Apoptotic cells were identified
in paraffin-embedded sections by TUNEL, using the ApopTag Plus 0.1% Tween-20 and incubated for 1 hr with peroxidase-conjugated
sheep anti-rabbit IgG (for Pan-Myc) or anti-rat IgG (for E cadherin)Peroxidase kit (Intergen), and the sections were counterstained with
methylene blue. (Amersham) diluted 1:2000 in the same buffer as the primary anti-
bodies. Filters were washed as before, and immune complexes werePrimary antibodies were as follows: rabbit polyclonals included
Pan-Myc antibodies (Moore et al., 1987); HL7 murine estrogen re- detected by ECL-Plus (Amersham).
ceptor antibody (kindly provided by Drs. Andreas Sewing and Hart-
mut Land); Ki-67 (Novacastra); Nkx6.1 antibody (a kind gift from Culture of Swiss 3T3 Cells
Ole Madsen, NovoNordisk); Isl-1 antibody (a kind gift from Helena S3T3 cells were grown to 40% confluence in DMEM supplemented
Edlund, University of Umea); glucagon antibody (Dako); somato- with 10% FCS. S3T3 cells were lysed directly on dishes using the
statin antibody (Dako); laminin (Sigma); guinea pig anti-porcine insu- same buffers as described above.
lin (Dako); purified rat anti-mouse CD31 (Pharmingen); and rat anti-
mouse E cadherin, (Zymed). Specificity of staining with Pan-Myc Assay of Blood and Urinary Glucose
and HL7 antibodies was demonstrated by preincubation with 2 g/ml All animals used in these studies were adults between 3 and 8
of their cognate peptide immunogen for 30 min at room temperature. months of age. For blood glucose measurement, mice were fasted
Pan-Myc, HL7, E cadherin, and CD31 antibodies were found to for 4 hr and then placed into a heat chamber (32C) for approximately
label reliably only frozen tissue sections. Other antibodies were 10 min to induce vasodilation. Blood (0.2 ml) was collected from tail
effective when used on both paraffin-embedded and frozen sec- veins, and glucose concentration was determined using a Gluco-
tions, although Ki-67, Nkx6.1, and laminin antibodies required epi- Trend 2 kit (Roche). Diastix test strips were used to determine urinary
tope retrieval by microwaving paraffin-embedded sections at 700 glucose concentrations.
W for 2  10 min in 0.01 M citrate buffer (pH 6.0) (Vector) followed
by immersion in cold water. Activation of c-MycERTAM by Administration
Antibodies were diluted in incubation buffer: PBS/0.5% Triton of 4-Hydroxytamoxifen (4-OHT)
X-100 containing 1:25 dilution of serum from the same species as the To activate c-MycERTAM protein in pancreatic -cells of adult trans-
secondary antibody. For all antibodies except CD31 and double genic mice, 1 mg of 4-OHT (Sigma) sonicated in peanut oil (1 mg/
immunofluorescence staining with E cadherin/Pan-Myc, TUNEL/ 0.2 ml) was administered daily by IP injection. Control wild-type and
Nkx6.1, or TUNEL/laminin, appropriate ABC Vectastain Elite kits RIP7-Bcl-xL also received daily IP injections of 4-OHT as appro-
(Vector) were used according to manufacturers’ instructions. La- priate. Untreated pIns-c-MycERTAM mouse controls received 0.2 ml
beled sections were lightly counterstained in hematoxylin. For CD31 IP peanut oil without 4-OHT daily.
immunofluorescence, rabbit anti-rat Ig-conjugated FITC (Vector)
was used as secondary antibody. For double E cadherin/Pan-Myc Acknowledgments
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